ICU Medical (ICUI) Q4 2011 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2011 earnings summary
6 Nov, 2026Executive summary
FY11 revenue rose 7% to a record $302.2M; diluted EPS was $3.15 reported and $2.59 excluding the Orbit sale gain.
Growth came from CLAVE, oncology, TEGO and international sales; critical care declined amid competition and pricing pressure.
Year-end cash, cash equivalents and investment securities totaled $160.0M, with no debt; operating cash flow reached a record $64.5M.
Financial highlights
Revenue was $302.2M vs. $283.0M in FY10; operating income was $65.2M vs. $47.7M, and net income was $44.7M vs. $29.9M.
Gross profit was $142.4M vs. $129.0M; net income includes a $14.2M gain on the Orbit asset sale and a $2.5M legal settlement benefit.
Excluding the Orbit sale gain, FY11 net income was a record $36.7M, or $2.59 diluted EPS.
Operating cash flow increased to $64.5M from $33.1M; cash and investment securities rose to $160.0M from $93.4M.
Outlook and guidance
FY12 revenue expectations: modest growth in domestic sales to Hospira, other domestic sales, and infusion therapy; significant oncology growth; lower critical care sales; moderate international growth.
FY12 SG&A expected at 26.5%–27.0% of revenue; R&D at 2.5%–3.0%; effective tax rate at ~35%.
FY12 capital expenditures estimated at $13M–$18M, primarily for U.S. manufacturing equipment and molds and global IT.
Slovakia plant was operating at 35% capacity at year-end; capacity utilization was expected to improve through 2012.
Latest events from ICU Medical
- Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020